Seaport Therapeutics Validates Glyph Platform in Science Translational Medicine Study

Seaport Therapeutics, a biotech firm founded by PureTech Health, has announced the publication of peer-reviewed research in the prestigious journal Science Translational Medicine regarding its SPT-300 candidate. The study identifies SPT-300 as the first triglyceride-mimetic prodrug to successfully achieve therapeutically relevant drug levels in human subjects. Utilizing the proprietary Glyph platform, the technology enables oral absorption through the lymphatic system, effectively bypassing first-pass metabolism in the liver. This publication serves as a critical scientific validation for the drug delivery platform, which aims to enhance the bioavailability of neuropsychiatric treatments. The successful demonstration of the Glyph platform's capabilities is expected to provide a positive catalyst for the valuation of its parent company, PureTech Health. This milestone underscores the significant potential for developing more effective oral therapies within the global biotechnology sector.

Sources:businesswire.comstreetinsider.comscience.orglasvegassun.cominvesting.comeurekalert.orgbenzinga.comtipranks.com